Table 1.
The epidemiological and clinicopathological characteristics of the patients
| Characteristics | Peritoneal cytology | p | |||
|---|---|---|---|---|---|
| Negative (n = 438) | Positive (n = 40) | ||||
| Group A Laparotomy (n = 232) |
Group B Laparoscopy (n = 206) |
Group C Laparotomy (n = 20) |
Group D Laparoscopy (n = 20) |
||
| Age, median (range) | 56.0 (27–84) | 55.5 (30–87) | 56.3 (43–71) | 53.2 (30–83) | 0.39 |
| Body mass index, median (range) | 24.5 (16.6–41.5) | 23.3 (17.3–36.0) | 22.7 (21.2–28.4) | 23.8 (19.5–29.6) | 0.31 |
| Follow-up duration (month), median (range) | 72.1 (4–148) | 41.6 (4–111) | 66.7 (9–114) | 29.3 (12–66) | < 0.05 |
| Lymph node resection, n (%) | 0.21 | ||||
| Sentinel LN | 0 (0%) | 61 (29.6%) | 0 (0%) | 8 (40.0%) | |
| PLN | 232 (100%) | 145 (70.4%) | 20 (100%) | 12 (60.0%) | |
| Differential of endometrioid EC, n (%) | 0.23 | ||||
| Grade 1 | 186 (80.2%) | 180 (87.4%) | 20 (100%) | 12 (60.0%) | |
| Grade 2 | 46 (19.8%) | 36 (12.6%) | 0 (0%) | 8 (40.0%) | |
| Postoperative adjuvant therapy, n (%) | 0 (0%) | 0 (0%) | 3 (15.0%) | 5 (25.0%) | 0.38 |
| Chemotherapy | 0 (0%) | 0 (0%) | 3 (15.0%) | 5 (25.0%) | |
| Radiotherapy | 0 (0%) | 0 (0%) | 0 (0%)) | 0 (0%) | |
| Recurrent sites, n (%) | n = 4 | n = 3 | n = 4 | n = 3 | < 0.05 |
| Intra-abdominal site | 2 (50.0%) | 1 (33.3%) | 4 (100%) | 3 (100%) | |
| Vagina | 1 (25.0%) | 1 (33.3%) | 1 (25.0%) | 1 (33.3%) | |
| Pelvic | 1 (25.0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Peritoneum | 0 (0%) | 0 (0%) | 3 (75.0%) | 2 (66.7%) | |
| Extra-abdominal site | 2 (50.0%) | 2 (66.7%) | 0 (0%) | 0 (0%) | |
| Liver | 1 (25.0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Lung | 1 (25.0%) | 1 (33.3%) | 0 (0%) | 0 (0%) | |
| Nodal | 0 (0%) | 1 (33.3%) | 0 (0%) | 0 (0%) | |
Sentinel LN sentinel lymph node biopsy, PLN pelvic lymph node dissection